ESA Data On Survival Benefit In Renal Transplant Grafts Are Insufficient - Medicare Panel

The MedCAC review focused narrowly on the benefit of using ESAs - Amgen's Aranesp (darbepoetin alfa) and Centocor Ortho Biotech's Procrit (epoetin alfa) - in transplant graft survival for kidney patients.